The EQ-5D questionnaire was self-completed before randomization in the OPTIMOX1 , a phase III trial comparing two strategies of FOLFOX chemotherapy which included 620 previously untreated mCRC patients recruited from January 2000 to June 2002 from 56 institutions in five countries .